Society of Gynecologic Oncology
Chicago, IL USA

Our News on Newswise

Newswise: 65d423d6b827d_527729028481bdbf5668fo.jpg

Society of Gynecologic Oncology to Host 2024 Annual Meeting on Women’s Cancer® March 16-18 in San Diego, California

Since 1970, health care professionals have convened at the Society of Gynecologic Oncology (SGO)’s Annual Meeting on Women’s Cancer® to discuss the latest in gynecologic cancer care and science, receive educational programming, and network....
19-Feb-2024 10:05 PM EST Add to Favorites

Newswise: 65c2e44c767ea_52811544752dd11fd19beo3.jpg

The Foundation for Women’s Cancer to Host Free Patient and Advocates Education Forum in San Diego

The Foundation for Women’s Cancer (FWC) is pleased to host a free Patient and Advocate Education Forum on​​ Friday, March 15, 2024, 10 a.m. – 4:30 p.m. PT, in San Diego, CA, at the San Diego Convention Center. The organization welcomes all...
13-Feb-2024 8:05 AM EST Add to Favorites

Foundation for Women's Cancer Commemorates Gynecologic Cancer Awareness Month with Vital Educational Outreach and Resourceful Toolkit

The Foundation for Women’s Cancer (FWC) recognizes September as Gynecologic Cancer Awareness Month annually, and this year is sharing an array of impactful resources aimed at raising awareness about gynecologic cancers and promoting education. FWC...
31-Aug-2023 9:05 PM EDT Add to Favorites

Two Clinical Trials Reveal Addition of Immunotherapy to Chemotherapy Regimen Increases Progression-Free Survival in Endometrial Cancer Patients

The results of two clinical trials, presented today at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer, showcased adding immunotherapy to standard chemotherapy resulted in significantly longer progression-free...
26-Mar-2023 1:00 PM EDT Add to Favorites

Trial’s Long-Term Follow-Up Data Shows No Difference in Overall Survival Among Ovarian Cancer Patients Who Did and Did Not Receive Parp Inhibitor Maintenance Therapy

After resolving missing data burdens, the ENGOT-OV16/NOVA (NCT01847274) study data shows no difference in overall survival for platinum-sensitive recurrent ovarian cancer (PSROC) patients who received PARP inhibitor niraparib maintenance therapy...
23-Mar-2023 6:00 AM EDT Add to Favorites

Gynecologic Cancer Patients Report Time-Related Burdens and Financial Toxicities Impact Quality of Life

Time-related and financial burdens are detrimental to gynecologic cancer patient and survivor quality of life (QOL), according to two research studies presented yesterday and today at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on...
23-Mar-2023 6:00 AM EDT Add to Favorites

Clinical Trial Participation Associated with Improved Overall Survival in Ovarian Cancer Patients

Clinical trial participation was associated with improved overall survival (OS) compared to standard of care therapy among women with platinum-resistant epithelial ovarian cancer (EOC), according to a research study presented today at the Society of...
23-Mar-2023 6:00 AM EDT Add to Favorites

Study Finds Intriguing Outcomes in Ovarian Cancer Patients Treated with PARP Inhibitors Before Surgical Intervention and Subsequent Chemotherapy

Administering PARP inhibitor (PARPi) olaparib prior to surgical intervention and chemotherapy in ovarian cancer patients – a new approach – is feasible and resulted in favorable surgical options, managed adverse events, and positive health...
23-Mar-2023 6:00 AM EDT Add to Favorites

See All News

Our YouTube Videos

Youtube feed not yet configured. Is this your Newswise member page? Contact to configure this module.


The SGO mission is to promote the highest quality of comprehensive clinical care through education and research in the prevention and treatment of gynecologic cancers. Our vision is to eradicate gynecologic cancers.


Kelly Clark
Marketing Manager

Elizabeth Kix, MPH, APR
Chief Marketing and Communications Officer


Kayla Nixon
Communications Manager



Instagram feed not yet configured. Click "Edit Instagram Feed" to enter your Instagram details.